Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.15720
Abstract: Symptomatic dermographism (SD, formerly also known as urticaria factitia) is a form of chronic inducible urticaria (CIndU) characterized by chronic itch and the development of itchy wheals upon skin exposure to friction, for example after… read more here.
Keywords: symptomatic dermographism; dermographism; benralizumab treatment; patient chronic ... See more keywords
Benralizumab for the treatment of asthma.
Sign Up to like & getrecommendations! Published in 2017 at "Drugs of today"
DOI: 10.1358/dot.2017.53.12.2736670
Abstract: Benralizumab is a humanized monoclonal antibody directed at the a subunit of the interleukin-5 receptor (IL-5R) that is under clinical development. The binding of benralizumab with the alpha chain of IL-5R results in inhibition of… read more here.
Keywords: benralizumab treatment; treatment asthma; benralizumab;
Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.865318
Abstract: Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and anti-IL-5α receptor antibodies (benralizumab), are indicated for severe asthma. While high-dose mepolizumab is also indicated for EGPA, benralizumab is indicated only for severe asthma.… read more here.
Keywords: egpa benralizumab; efficacy benralizumab; benralizumab treatment; treatment ... See more keywords